Skip to main content

Boehringer Ingelheim – Schizophrenia

 

The study is looking to investigate the effect on cognition and function capacity in Schizophrenia patients

Sponsors: Boehringer Ingelheim

Phase : 2

Indication: Schizophrenia

Age: 18 years to 50 years

Category: Treatment

For more information regarding the study: https://clinicaltrials.gov/ct2/show/NCT03351244

Studies Currently Available At

Sign Up For This Study